^
25d
CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
P1, N=111, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Dec 2025 --> Feb 2028
Trial primary completion date • Metastases
|
JNJ-6420
1m
CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
P1, N=111, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2026 --> Aug 2028
Trial completion date
|
JNJ-6420
9ms
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
P1, N=111, Recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Mar 2025 --> Dec 2025
Trial completion date • Trial primary completion date • Metastases
|
JNJ-6420
1year
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
P1, N=111, Recruiting, Janssen Research & Development, LLC | N=76 --> 111 | Trial completion date: Jul 2025 --> Oct 2025
Enrollment change • Trial completion date • Metastases
|
JNJ-6420
1year
Enrollment change • Metastases
|
JNJ-6420
over1year
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
P1, N=100, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2025 --> Jul 2025 | Trial primary completion date: Mar 2023 --> Mar 2025
Trial completion date • Trial primary completion date
|
JNJ-6420
over2years
Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer. (ASCO 2022)
Secondary endpoints include prostate specific antigen response rate, overall response rate (PCWG3 modified RECIST 1.1 criteria), PK, PD, immunogenicity, and biomarker analyses. Enrollment began in Dec 2020; as of 10 Feb 2022, 4 sites have been initiated and 23 patients enrolled; currently, dose escalation is ongoing.
P1 data • IO biomarker
|
AR (Androgen receptor) • KLK2 (Kallikrein-related peptidase 2)
|
JNJ-6420
almost3years
Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer. (ASCO-GU 2022)
Secondary endpoints include prostate specific antigen response rate, overall response rate (PCWG3 modified RECIST 1.1 criteria), PK, PD, immunogenicity, and biomarker analyses. Enrollment began in Dec 2020; as of Sep 2021, 4 sites have been initiated and 14 pts enrolled; currently, dose escalation is ongoing.
P1 data • IO biomarker
|
AR (Androgen receptor) • KLK2 (Kallikrein-related peptidase 2)
|
JNJ-6420